Bioinformatics

The BostonGene Tumor Portrait™ Test depicts tumor activity, tumor cellular composition, immune microenvironment activity, and other tumor-associated processes to identify active or suppressed processes in patient tumors to ultimately guide therapeutic decision-making.

Tumor Clonal composition is computed based on the mutational profile. Clonal composition module depicts the proportion of malignant cells sharing the same mutations (a clone) and describes clonality (the number of different malignant cells clones). Clonal Evolution describes changes of malignant clonal composition during disease progression or treatment response.

Detecting novel and recurrent gene fusions.

Accurate measure of expressions of more than 100,000 transcripts and 20,000 genes, including different splice variants.

Robust point mutations, indels, copy number alterations calling using tumor / normal pair across entire exome, including overall tumor mutational burden (TMB), homologous recombination deficiency (HRD), genome instability and loss of heterozygosity.

BostonGene cancer reactive profiling of T and B cells immune cell repertoire in the tumor microenvironment in solid cancer as well as the identification of major malignant clones of T and B cells in hematological malignancies leads to a better understanding of tumor progression and evolution.

Predicting tumor antigenicity by calculating expressed neoantigenic peptides derived from mutated and fusion proteins.

Analyzing functional and transcriptomic effects of genomic alterations by utilizing complete spectrum of protein-protein interactions in a comprehensive map of signaling pathways.

BostonGene detects cancer-associated viral or bacterial infections as these are incredibly important for diagnostics and therapy selection.

Immunotherapy reactive cellular components of the tumor microenvironment, an important component of tumor biology and activity, will be deciphered using BostonGene AI-driven technologies.